ALAMEDA, CA--(Marketwired - May 23, 2013) - Singulex, Inc., a privately held commercial-stage company committed to improving patient care and enabling the reduction of healthcare costs by providing high-value, advanced tests and systems for the diagnosis and monitoring of chronic diseases, today announced that Guido Baechler has been appointed President and Chief Executive Officer of the company effective immediately. Baechler, previously Singulex's Senior Vice President of Operations, also brings two decades of leadership experience from Roche Diagnostics in research, development, marketing and executive management, to the role of CEO. Baechler's succession to CEO is timed with the departure of Singulex's current CEO, Philippe Goix. Baechler will join the Singulex Board.
"Philippe's passion and entrepreneurial insight formed the basis of Singulex's novel technology platform as well as the vision for commercializing our digital immunoassay tests for cardiovascular chronic disease management," said Heiner Dreismann, Lead Director. "We wish him the best of luck as he pursues new business interests."
Dreismann also added, "Guido has a track record of success in building teams, forming strategic partnerships and leading businesses across global organizations, and he has played a pivotal role in Singulex's overall success to date. The Board's appointment of him to CEO sets the stage for Singulex's future growth while capitalizing on the company's culture that has attracted top talent and business partners."
Baechler joined Singulex in 2008. As Senior Vice President of Operations, he established successful commercial lab operations and has led the development of a second-generation diagnostic platform, which is a key element of the company's growth strategy. From 1989 until 2008, Baechler held leadership positions in research and development, marketing and executive program management at Roche Diagnostics in the United States and Switzerland.
"I look forward to leading Singulex as we work to maximize opportunities within our Diagnostics business, as well as our Cardiovascular Disease Management and Life Science businesses," said Baechler. "We are well positioned for success with a strong team, revenue momentum and a strategy that positions us for continued growth that makes meaningful contributions to medical communities around the world."
About Singulex, Inc.
Singulex's vision is to transform chronic disease management, improving patient care and health while reducing healthcare costs. Singulex's proprietary digital immunoassay platform significantly increases the diagnostic and prognostic power of established biomarkers. This enables physicians to individualize treatment strategies, monitor effectiveness of therapy and encourage patient adherence through feedback. Improved patient outcomes and the reduced need for costly, invasive diagnostic procedures translate into healthcare cost savings. The Singulex CLIA-certified laboratory offers a comprehensive menu of advanced cardiovascular disease testing to physicians in the U.S. At leading pharmaceutical R&D laboratories, academic institutions and clinical research organizations (CROs) around the world, digital immunoassay technology from Singulex is powering discovery and development of innovative diagnostics and treatments for chronic diseases such as CVD, Alzheimer, arthritis and diabetes. For further information, visit www.singulex.com.